Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas

European Journal of Cancer

Volumn 51, Issue 17, 2015, Pages 2698-2707

  Kim, Sehui ^a,b   Kim, Moon Young ^a   Koh, Jaemoon ^a,b   Go, Heounjeong ^c   Lee, Dong Soo ^a,b   Jeon, Yoon Kyung ^a,b   Chung, Doo Hyun ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Cancer immunotherapy; Pleomorphic carcinoma of the lung; Programmed death 1; Programmed death 1 ligand 1; Sarcomatoid carcinoma of the lung

Indexed keywords

CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CARCINOMATOSIS; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MALE; PLEOMORPHIC CARCINOMA OF THE LUNG; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SMOKING; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SARCOMA; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; SARCOMA; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84970978445     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.08.013     Document Type: Article

References (28)

1. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, and C.C. Harris Pathology and genetics of tumours of the lung, pleura, thymus, and heart 2004 IARC Press Lyon
2. N.F. Fishback, W.D. Travis, C.A. Moran, D.G. Guinee Jr., W.F. McCarthy, and M.N. Koss Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases Cancer 73 12 1994 2936 2945
3. N. Venissac, D. Pop, S. Lassalle, F. Berthier, P. Hofman, and J. Mouroux Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease? J Thorac Cardiovasc Surg 134 3 2007 619 623
4. Y. Lin, H. Yang, Q. Cai, and et al. Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma Am J Clin Oncol 2014
5. A. Italiano, A.B. Cortot, M. Ilie, and et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy Int J Cancer 125 10 2009 2479 2482
6. X. Jiang, Y. Liu, C. Chen, and et al. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases Clin Lung Cancer 13 4 2012 288 296
7. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 4 2012 252 264
8. M.F. Sanmamed, and L. Chen Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation Cancer J 20 4 2014 256 261
9. T. Okazaki, and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int Immunol 19 7 2007 813 824
10. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, and et al. Safety and activity of Anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
11. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
12. M.Y. Kim, J. Koh, S. Kim, H. Go, Y.K. Jeon, and D.H. Chung Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers Lung Cancer 88 1 2015 24 33
13. J. Koh, H. Go, B. Keam, and et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status Mod Pathol 2015
14. V. Velcheti, D.L. Rimm, and K.A. Schalper Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) J Thorac Oncol 8 6 2013 803 805
15. V. Velcheti, K.A. Schalper, D.E. Carvajal, and et al. Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 94 1 2014 107 116
16. Y.B. Chen, C.Y. Mu, and J.A. Huang Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study Tumori 98 6 2012 751 755
17. N. Tiwari, A. Gheldof, M. Tatari, and G. Christofori EMT as the ultimate survival mechanism of cancer cells Semin Cancer Biol 22 3 2012 194 207
18. G. Pelosi, A. Sonzogni, T. De Pas, and et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview Int J Surg Pathol 18 2 2010 103 120
19. C. Kudo-Saito, H. Shirako, T. Takeuchi, and Y. Kawakami Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells Cancer Cell 15 3 2009 195 206
20. I. Akalay, B. Janji, M. Hasmim, and et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis Cancer Res 73 8 2013 2418 2427
21. L. Chen, D.L. Gibbons, S. Goswami, and et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression Nat Commun 5 2014 5241
22. H.L. Kundel, and M. Polansky Measurement of observer agreement Radiology 228 2 2003 303 308
23. C.Y. Mu, J.A. Huang, Y. Chen, C. Chen, and X.G. Zhang High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 3 2011 682 688
24. M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, and et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 8 2009 1537 1544
25. Y. Zhang, S. Huang, D. Gong, Y. Qin, and Q. Shen Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer Cell Mol Immunol 7 5 2010 389 395
26. Y. Shang, X. Cai, and D. Fan Roles of epithelial-mesenchymal transition in cancer drug resistance Curr Cancer Drug Targets 13 9 2013 915 929
27. J.M. Taube, A. Klein, J.R. Brahmer, and et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 19 2014 5064 5074
28. E.B. Garon, N.A. Rizvi, R. Hui, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 21 2015 2018 2028